ERBB2 and neoplasm: The most recent CAP template updates on 19 March 2025 provide updated guidance for pathologists to report HER2-ultralow, i.e., IHC 0 with membrane staining that is incomplete and is faint / barely perceptible and in ≤ 10% of tumor cells.